Literature DB >> 17451201

Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.

Li-Cheng Dai1, Xiang Wang, Xing Yao, Yong-Liang Lu, Jin-Liang Ping, Jian-Fang He.   

Abstract

AIM: To evaluate the effect of antisense oligonucleotide targeting midkine (MK-AS) on angiogenesis in chick chorioallantoic membrane (CAM) and in situ human hepatocellular carcinoma (HCC).
METHODS: An in situ human hepatocellular carcinoma (HCC) model and CAM assay were used in this experiment. The effect of MK-AS on angiogenesis was evaluated by cell proliferation assay and hematoxylin-eosin (HE) staining.
RESULTS: MK-AS significantly inhibited human umbilical vein endothelial cells (HUVEC) and in situ human HCC growth. At the same time, MK-AS suppressed the angiogenesis both in human hepatocellular carcinoma cell line (HEPG2)-induced CAM and in situ human HCC tissues.
CONCLUSION: MK-AS is an effective antiangiogenesis agent in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451201      PMCID: PMC4146995          DOI: 10.3748/wjg.v13.i8.1208

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Angiogenesis in bladder cancer--prognostic marker and target for future therapy.

Authors:  Edward H Streeter; Adrian L Harris
Journal:  Surg Oncol       Date:  2002-06       Impact factor: 3.279

Review 3.  Angiogenic and angiostatic factors in the molecular control of angiogenesis.

Authors:  J H W Distler; A Hirth; M Kurowska-Stolarska; R E Gay; S Gay; O Distler
Journal:  Q J Nucl Med       Date:  2003-09

4.  cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis.

Authors:  K Kadomatsu; M Tomomura; T Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  1988-03-30       Impact factor: 3.575

5.  Immunohistochemical analysis of midkine expression in human prostate carcinoma.

Authors:  N Konishi; M Nakamura; S Nakaoka; Y Hiasa; M Cho; H Uemura; Y Hirao; T Muramatsu; K Kadomatsu
Journal:  Oncology       Date:  1999-10       Impact factor: 2.935

6.  Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by Midkine.

Authors:  M Qi; S Ikematsu; K Ichihara-Tanaka; S Sakuma; T Muramatsu; K Kadomatsu
Journal:  J Biochem       Date:  2000-02       Impact factor: 3.387

7.  Molecular cloning of the 18-kDa growth-associated protein of developing brain.

Authors:  J Merenmies; H Rauvala
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

8.  Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.

Authors:  Gerald E Stoica; Angera Kuo; Ciaran Powers; Emma T Bowden; Elaine Buchert Sale; Anna T Riegel; Anton Wellstein
Journal:  J Biol Chem       Date:  2002-07-16       Impact factor: 5.157

9.  Midkine induced growth of ameloblastoma through MAPK and Akt pathways.

Authors:  F Sandra; H Harada; N Nakamura; M Ohishi
Journal:  Oral Oncol       Date:  2004-03       Impact factor: 5.337

10.  Endothelial proliferation in tumours and normal tissues: continuous labelling studies.

Authors:  B Hobson; J Denekamp
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

View more
  7 in total

1.  Neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, interacts with pleiotrophin, a heparin-binding growth factor.

Authors:  Keiko Nakanishi; Yoshihito Tokita; Sachiko Aono; Michiru Ida; Fumiko Matsui; Yujiro Higashi; Atsuhiko Oohira
Journal:  Neurochem Res       Date:  2010-04-06       Impact factor: 3.996

2.  Inhibitory effect of midkine-binding peptide on tumor proliferation and migration.

Authors:  Hui-Lian Huang; Jian-Fen Shen; Li-Shan Min; Jin-Liang Ping; Yong-Liang Lu; Li-Cheng Dai
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 4.  Midkine translocated to nucleoli and involved in carcinogenesis.

Authors:  Li-Cheng Dai
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

Review 5.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

Review 6.  Midkine-A novel player in cardiovascular diseases.

Authors:  Marina Majaj; Ludwig T Weckbach
Journal:  Front Cardiovasc Med       Date:  2022-09-20

Review 7.  Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury.

Authors:  Emily Ross-Munro; Faith Kwa; Jenny Kreiner; Madhavi Khore; Suzanne L Miller; Mary Tolcos; Bobbi Fleiss; David W Walker
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.